Peptide Macrocycles Against Resistant Acinetobacter baumannii
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Acinetobacter baumannii has developed significant antibiotic resistance, making it difficult to treat infections caused by this bacterium, particularly in intensive care units, with limited treatment options and high mortality rates due to its ability to upregulate and acquire resistance determinants.
Innovation Solution
Development of novel peptide macrocycles that exhibit activity against both drug-susceptible and drug-resistant strains of Acinetobacter baumannii, demonstrating potential through pharmacokinetic profiling and efficacy in a mouse septicemia model.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Acinetobacter baumannii infections, then treatment options are limited, but antibiotic resistance develops making the bacteria difficult to treat
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of peptide compounds to create macrocyclic forms with improved pharmacological properties. Specifically, the invention transforms linear peptides into cyclic structures through various linkages (amide, ester, ether, etc.), which alters key parameters including molecular stability, conformational flexibility, and binding affinity to bacterial targets, thereby achieving effectiveness against resistant strains
Solution Approach 2:
The patent applies composite material principles by creating hybrid molecular structures that combine peptide backbones with macrocyclic frameworks. These composite structures integrate the bioactivity of peptides with the enhanced stability and membrane permeability of macrocycles, resulting in compounds that can overcome bacterial resistance mechanisms while maintaining therapeutic efficacy
2Reliability
If new peptide macrocycles are developed to treat resistant strains, then treatment options improve, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the macrocyclic structure into modular components: a peptide core segment, a macrocyclic linking segment, and various substitutable R-groups. This modular architecture allows systematic variation of individual segments to optimize activity against resistant strains while maintaining a manageable design framework that simplifies the overall development process
Solution Approach 2:
The patent implements universality through a platform approach where the core macrocyclic structure serves multiple functions: it provides structural stability, enables membrane permeability, and offers a scaffold for attaching various bioactive peptide sequences. This multi-functional design allows the same macrocyclic framework to be adapted against multiple resistant strains and different bacterial targets, reducing overall development complexity
3Reliability
If peptide macrocycles are designed with specific structures to target bacterial mechanisms, then efficacy against Acinetobacter baumannii improves, but the difficulty of identifying effective structures increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and structural features at particular positions within the macrocyclic framework (indicated by various R-groups at positions R1-R8). These localized modifications create specific interactions with bacterial targets such as ribosomal binding sites or cell membrane components, enabling precise targeting of Acinetobacter baumannii while maintaining overall structural integrity and activity
Data Source
AI summary
The present invention provides compounds of formula (I)wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.